SOURCE-LINKED STUDY SUMMARY
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Abstract summarizedQuality not appraised
- What was studied
- This preclinical discovery program sought a once-weekly GLP-1 analogue with stronger albumin binding and stability against metabolic degradation.
- Who / model studied
- The abstract describes molecular optimization and pharmacokinetic testing in mini-pigs; it does not report a human efficacy trial or participant count.
- Studied dose & schedule
- Dose and schedule have not yet been extracted for this summary.
- What the study found
- Semaglutide was selected as the candidate. Compared with liraglutide, GLP-1-receptor affinity was threefold lower but albumin affinity was higher; mini-pig exposure supported once-weekly development.
- Limitations & context
- This abstract provides preclinical pharmacology, not evidence of human effectiveness or safety; semaglutide was still in phase 3 testing at publication.
Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1021/acs.jmedchem.5b00726